Cytori Therapeutics, Inc. (NASDAQ: CYTX) is committed to becoming the global leader in regenerative medicine. The company focuses on providing patients with new options for reconstructive and aesthetic surgery, developing treatments for cardiovascular disease, and banking adipose-derived, adult stem and regenerative cells (ADRCs). To meet its objective, Cytori developed Celution® Technology to separate and concentrate a patient’s own ADRCs for delivery back to the same patient in a single surgical procedure. For further information, visit the Company’s web site at www.cytoritx.com.
- 17 years ago
QualityStocks
Cytori Therapeutics, Inc. (NASDAQ: CYTX)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…